Synovial Cell Gene Editing to Reduce Osteoarthritis Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis and joint dysfunction lack effective long-term solutions for symptomatic relief and joint function restoration, and are hindered by systemic inflammation driven by increased levels of pro-inflammatory cytokines.
Innovation Solution
Gene-editing synovial cells and synoviocytes to reduce the expression of inflammatory cytokines such as IL-1α and IL-1β using CRISPR-Cas9, TALE, or zinc finger methods, delivered via an adeno-associated virus (AAV) system, to target and silence or reduce cytokine and growth factor genes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for osteoarthritis are used, then symptomatic relief may be achieved temporarily, but long-term joint function restoration is ineffective and disease progression continues due to systemic inflammation
Solution Approach 1:
The patent applies preliminary action by using gene-editing technology to proactively modify synovial cells before osteoarthritis fully develops or progresses. By editing IL-1α and IL-1β genes in synovial cells ahead of time, the treatment prevents the inflammatory cascade that leads to cartilage degradation, thereby achieving long-term disease prevention rather than temporary symptom management
Solution Approach 2:
The patent converts the harmful role of IL-1α and IL-1β cytokines into a benefit by using gene-editing to selectively reduce their expression. These cytokines normally drive inflammation and cartilage breakdown, but by programmatically reducing their levels through CRISPR-Cas9 or similar technologies, the treatment transforms the inflammatory pathway from a disease driver into a controlled therapeutic target, achieving sustained joint protection
2Reliability
If gene-editing is used to reduce inflammatory cytokine expression, then inflammation is reduced and joint function improves, but the complexity of the treatment increases
Solution Approach 1:
The patent uses adeno-associated virus (AAV) vectors as intermediaries to deliver gene-editing components into synovial cells. The AAV vector serves as a mediator that packages and transports the CRISPR-Cas9 system or RNA interference molecules into the target cells, simplifying the delivery process while achieving precise gene editing. This intermediary approach reduces the complexity of direct gene editing by using a natural viral delivery system
Solution Approach 2:
The gene-editing treatment applies self-service by programming synovial cells to autonomously regulate their own IL-1α and IL-1β expression levels. Once the gene-editing components are delivered, the modified synovial cells continuously produce reduced levels of inflammatory cytokines without requiring external intervention, thereby maintaining long-term anti-inflammatory effects through the cells' own regulatory mechanisms
Data Source
AI summary
The present invention provides compositions and methods for treating joint disorders that are characterized by an inflammatory component. In some aspects, the compositions and methods are to prevent the progression of osteoarthritis and other arthritides and to treat osteoarthritis and other arthritides in a mammalian joint.